Zymergen's Implosion Makes Amyris a Screaming Buy
Zymergen (NASDAQ: ZY) stock recently collapsed, after the synthetic-biology start-up reminded investors that raising money for a new synthetic biology, or synbio, business is a lot easier than making money in this topsy-turvy industry. In a nutshell, the company's founder and CEO, Josh Hoffman, is leaving the company after overpromising and underdelivering.
Grizzled synbio investors who understand the ins and outs of this burgeoning industry weren't at all surprised by Zymergen's devastating update. It was simply an admission of issues that synbio industry pioneer Amyris (NASDAQ: AMRS) figured out years ago.
Image source: Getty Images.
Source Fool.com
